FATE THERAPEUTICS INC Prepaid Expense and Other Assets, Current
FATE THERAPEUTICS INC (FATE) had Prepaid Expense and Other Assets, Current of $3.48 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-13
- 2026-06-30: Prepaid Expense and Other Assets, Current $3.48M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $4.00M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $4.13M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $5.15M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.48M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $4.13M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $6.17M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $5.39M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $9.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $9.24M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $13.46M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $9.97M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $14.54M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $12.90M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $11.41M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $15.49M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $27.37M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $19.97M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $17.18M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $11.45M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $8.83M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $7.70M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $7.37M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $7.24M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $5.89M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $4.73M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.10M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $4.96M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.66M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $2.81M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $3.17M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $2.90M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $3.69M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $2.24M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $2.02M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $1.49M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.65M 10-K · filed 2019-03-05 | |
| 2017-09-30 | $825.00K 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $848.00K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $1.14M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $1.21M 10-K · filed 2018-03-05 | |
| 2016-09-30 | $780.00K 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $1.16M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $955.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $843.00K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $482.00K 10-Q · filed 2015-11-03 | |
| 2015-06-30 | $395.00K 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $443.00K 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $760.00K 10-K · filed 2016-03-03 | $771.00K 10-K · filed 2015-03-12 |
| 2014-09-30 | $94.00K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $233.00K 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $382.00K 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $615.00K 10-K · filed 2015-03-12 | |
| 2013-09-30 | $304.00K 10-Q · filed 2013-11-13 | |
| 2012-12-31 | $706.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |